Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis
J Am Acad Dermatol 2025;92:1015-23 DOI: 10.1016/j.jaad.2024.12.025
Chen et al. investigated the risk of MACE and VTE among patients with biologic-naïve psoriasis or PsA receiving biologic therapy. No significant difference in the risks of MACE and VTE was found between new biologics (IL-17i, IL-12/23i, or IL-23i) and TNFi.
No statistically significant difference in the risks of MACE and VTE was found between biologics, despite slight differences of median values and results were consistent in subgroup analyses of patients with only psoriasis or only PsA.
Keywords:
